Health and Healthcare

Gilead Sciences : GILD

All Gilead Sciences Articles

730 Articles

Jon C. Ogg | Oct 26, 2017 at 4:18 PM EDT

Gilead Earnings Bring Mixed Results

Gilead Corporation (NASDAQ: GILD) has joined other biotech giants in releasing its earnings for the third quarter of 2017. The…

Chris Lange | Oct 25, 2017 at 10:40 AM EDT

Short Sellers Chase Biotechs Higher

The October 13 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Oct 22, 2017 at 10:45 AM EDT

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.

Jon C. Ogg | Oct 19, 2017 at 12:15 PM EDT

Does Gilead’s CAR T Approval Vindicate the High Acquisition Price for Kite Pharma?

Now there is a new FDA approval Gilead's CAR T lymphoma treatment named Yescarta that has created at least some…

Jon C. Ogg | Oct 12, 2017 at 2:05 PM EDT

Are Analysts Secretly Calling Gilead a Screaming Buy?

Sometimes it turns out that great growth companies eventually run into the day when getting the growth of the past…

Chris Lange | Oct 11, 2017 at 11:35 AM EDT

Short Sellers Grow More Selective on Major Biotechs

The September 29 short interest data have been compared with the previous report, and short interest in the selected biotech…

Jon C. Ogg | Oct 11, 2017 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: AbbVie, Amazon, Facebook, Johnson & Johnson, Schlumberger, Visa, Walmart and More

The top analyst upgrades, downgrades and other research calls from Wednesday include AbbVie, Gilead, Johnson & Johnson, Potash, Schlumberger, Visa…

Jon C. Ogg | Oct 5, 2017 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: CarMax, DowDuPont, Gilead, GrubHub, Microsoft, Nike, Western Digital and More

The top analyst upgrades, downgrades and other research calls from Thursday include CarMax, DowDuPont, Gilead Sciences, GrubHub, Microsoft, Nike and…

Jon C. Ogg | Oct 4, 2017 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: Freeport-McMoran, Gilead, FuelCell, Oracle, Take-Two, Tesla, Waste Management and More

The top analyst upgrades, downgrades and other research calls from Wednesday include Freeport-McMoran, Gilead Sciences, FuelCell, Oracle, Take-Two Interactive, Tesla…

Chris Lange | Sep 28, 2017 at 4:08 PM EDT

Thursday’s Biggest Winners and Losers in the S&P 500

Thursday was a relatively mixed day for the U.S. broad markets. Although all the major averages started off negative a…

Chris Lange | Sep 27, 2017 at 10:25 AM EDT

Short Sellers Hike Bets in Major Biotechs

The September 15 short interest data have been compared with the previous report, and short interest in all the selected…

Chris Lange | Sep 13, 2017 at 8:55 AM EDT

Short Sellers Hike Bets in Major Biotechs

The August 31 short interest data have been compared with the previous report, and short interest in most of the…

Jon C. Ogg | Aug 31, 2017 at 9:15 AM EDT

Top Analyst Upgrades and Downgrades: Abercrombie, Arch Coal, Baker Hughes, BioMarin, Gilead, Hasbro, Snap and More

The include Abercrombie & Fitch, Arch Coal, Baker Hughes, BioMarin Pharmaceutical, Gilead Sciences, Hasbro and Snap.

Chris Lange | Aug 28, 2017 at 10:00 AM EDT

Gilead Moves to Acquire Kite Pharma

Gilead Sciences shares have been in a holding pattern for a while. Analysts have said that the firm needs to…

Chris Lange | Aug 25, 2017 at 10:10 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Biotechs

The August 15 short interest data have been compared with the previous report, and short interest moves in the selected…

1 … 18 19 20 21 22 … 49

Gilead Sciences : GILD

All Gilead Sciences Articles

Gilead Earnings Bring Mixed Results

Short Sellers Chase Biotechs Higher

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

Does Gilead’s CAR T Approval Vindicate the High Acquisition Price for Kite Pharma?

Are Analysts Secretly Calling Gilead a Screaming Buy?

Short Sellers Grow More Selective on Major Biotechs

Top Analyst Upgrades and Downgrades: AbbVie, Amazon, Facebook, Johnson & Johnson, Schlumberger, Visa, Walmart and More

Top Analyst Upgrades and Downgrades: CarMax, DowDuPont, Gilead, GrubHub, Microsoft, Nike, Western Digital and More

Top Analyst Upgrades and Downgrades: Freeport-McMoran, Gilead, FuelCell, Oracle, Take-Two, Tesla, Waste Management and More

Thursday’s Biggest Winners and Losers in the S&P 500

Short Sellers Hike Bets in Major Biotechs

Short Sellers Hike Bets in Major Biotechs

Top Analyst Upgrades and Downgrades: Abercrombie, Arch Coal, Baker Hughes, BioMarin, Gilead, Hasbro, Snap and More

Gilead Moves to Acquire Kite Pharma

Short Sellers Can’t Make Up Their Minds on Major Biotechs

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Gilead Sciences : GILD

All Gilead Sciences Articles

Gilead Earnings Bring Mixed Results

Short Sellers Chase Biotechs Higher

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

Does Gilead’s CAR T Approval Vindicate the High Acquisition Price for Kite Pharma?

Are Analysts Secretly Calling Gilead a Screaming Buy?

Short Sellers Grow More Selective on Major Biotechs

Top Analyst Upgrades and Downgrades: AbbVie, Amazon, Facebook, Johnson & Johnson, Schlumberger, Visa, Walmart and More

Top Analyst Upgrades and Downgrades: CarMax, DowDuPont, Gilead, GrubHub, Microsoft, Nike, Western Digital and More

Top Analyst Upgrades and Downgrades: Freeport-McMoran, Gilead, FuelCell, Oracle, Take-Two, Tesla, Waste Management and More

Thursday’s Biggest Winners and Losers in the S&P 500

Short Sellers Hike Bets in Major Biotechs

Short Sellers Hike Bets in Major Biotechs

Top Analyst Upgrades and Downgrades: Abercrombie, Arch Coal, Baker Hughes, BioMarin, Gilead, Hasbro, Snap and More

Gilead Moves to Acquire Kite Pharma

Short Sellers Can’t Make Up Their Minds on Major Biotechs

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%